sorafenib has been researched along with at 13387 in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (at 13387) | Trials (at 13387) | Recent Studies (post-2010) (at 13387) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 59 | 4 | 57 |
| Protein | Taxonomy | sorafenib (IC50) | at 13387 (IC50) |
|---|---|---|---|
| Heat shock protein HSP 90-alpha | Homo sapiens (human) | 0.0437 | |
| Heat shock protein HSP 90-beta | Homo sapiens (human) | 0.138 | |
| Endoplasmin | Homo sapiens (human) | 0.022 | |
| Endoplasmin | Canis lupus familiaris (dog) | 0.013 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berglund, H; Hariri, M; Malmberg, C; Mortensen, ACL; Papalanis, E; Spiegelberg, D | 1 |
1 other study(ies) available for sorafenib and at 13387
| Article | Year |
|---|---|
Combination therapy of tyrosine kinase inhibitor sorafenib with the HSP90 inhibitor onalespib as a novel treatment regimen for thyroid cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Humans; Mice; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Tyrosine Kinase Inhibitors | 2023 |